ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1271

Myocarditis in Antisynthetase Syndrome

Céline Dieval1, Olivier Benveniste2, Christophe Deligny3, Alain Meyer4, Guillaume Lefevre5, Yoland Schoindre6, Aude Rigolet7 and Baptiste Hervier8, 1Internal Medicine, Rochefort Hospital, Rochefort, France, 2UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 3Internal Medicine, CHU Fort de France, Fort de France, France, 4Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 5Internal Medicine, CHRU Lille, Lille, France, 6DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, 7Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 8Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Myocardial involvement and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype

Session Type: Abstract Submissions (ACR)

Background/Purpose Antisynthetase syndrome (aSS) corresponds to an overlapping inflammatory myopathy identified by different myositis specific autoantibodies (directed against tRNA-synthetases). Myocardial involvement in this condition is poorly described.

Methods From a 342 aSS patient registry, nine cases of myocarditis were identified on the basis of an unexplained increased in cardiac troponin I levels associated with either suggestive cardiac magnetic resonance imaging (MRI) findings, normal coronary artery explorations, and/or positive endomyocardial biopsy.

Results The prevalence of myocarditis in aSS is 2.6% (n=9) and was not linked to any autoantibody specificity: anti-Jo1 (n=5), anti-PL7 (n=3) and anti-PL12 (n=1). Myocarditis was an inaugural presentation in 44% of the cases and was asymptomatic (n=1) or revealed by an acute (n=4) or subacute (n=4) cardiac failure. Of note, myocarditis was always associated with an active myositis. When performed (n=8), cardiac MRI revealed a late hypersignal in the T1-images in 87% of the cases (n=7). Four patients (44%) required intensive care. Seven patients (78%) received dedicated cardiotropic drugs. Steroids and at least one immunosuppressive drug were given in all cases. After a median follow-up of 23 months (range 2-51), six (67%) patients recovered whereas three (33%) developed chronic cardiac insufficiency. No patient died.

Conclusion The prevalence of myocarditis in aSS is similar to that reported in other inflammatory myopathies. Although it has a relatively good prognosis, myocarditis is a severe condition and should be carrefully explored in active aSS patients.


Disclosure:

C. Dieval,
None;

O. Benveniste,
None;

C. Deligny,
None;

A. Meyer,
None;

G. Lefevre,
None;

Y. Schoindre,
None;

A. Rigolet,
None;

B. Hervier,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myocarditis-in-antisynthetase-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology